HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases.
The laboratory of Prof. Lars Zender identified Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) as a key regulator of liver regeneration. Suppression of MKK4 gene expression by small RNA molecules unlocks the regenerative capacity of hepatocytes even in severely diseased livers. These findings paved the way for the unique an...
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases.
The laboratory of Prof. Lars Zender identified Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) as a key regulator of liver regeneration. Suppression of MKK4 gene expression by small RNA molecules unlocks the regenerative capacity of hepatocytes even in severely diseased livers. These findings paved the way for the unique and promising therapeutic concept to develop small molecule MKK4 inhibitors to treat acute and chronic liver diseases. In particular, following thorough characterization of the underlying molecular mechanism of drug.
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
